Is Buying US STEM CELL INCORPORATED (USRM) Here a Winning Strategy?

December 6, 2017 - By Louis Casey

Is Buying US STEM CELL INCORPORATED (USRM) Here a Winning Strategy?

Interested investors have been looking for information on shares of US STEM CELL INCORPORATED (OTCMKTS:USRM) after the stock moved $-0.0006, hitting the $0.0044 price point in a recent trade.

It’s the latest price, but let’s analyze how the stock has been doing recently. In the past year, US STEM CELL INCORPORATED’s stock was big mover. According to the short interest report published recently, (USRM) had 287,900 shorted shares for 0.1 days to cover. The prior short interest was 8,900 for a $3134.83 change. The 52-Week High and Low are noted here. -97.54 % (High), 120.00 %, (Low). The stock had 4.70M average volume.

Enroll for Our Newsletter Today and know if shares price of US STEM CELL INCORPORATED (OTCMKTS:USRM) is Ready to Breakout!

Penny stocks are often stated as risky investments that hardly pay off. Admittedly, there is fact to this, but with the right knowledge and tactics, it is possible to earn a significant amount of gain in penny stocks. Simply said, a penny stock is an equity that trades at a low price.

Irrespective of the name, penny stocks usually are priced over a penny, occupying a price range at or close to $1, though some are priced a fraction of a penny. Often referred to as micro-cap equities, the Securities & Exchange Commission classifies these types of securities as being $5 or less. Over-the-counter stocks are NOT listed on any of the formal exchanges.

So, penny stocks frequently fit in this segment, though many dodge this category. Over-the-counter (OTC) equities are stated to be risky as they aren’t contingent to the listing and reporting requirements of the reputed commodity exchanges.

Register in the Bar Below to Obtain Breaking Alerts on Shares That Are Set to Make a Move!

Penny shares can be listed on NASDAQ or other known stock exchanges, although many more cannot be found there. A major percentage of penny stocks are listed on the so-named ‘pink sheets’, i.e., daily news of OTC shares. They can even be seen on the ‘Over-the-Counter Bulletin Board.’ Commodities listed on the OTCBB fail to fulfill the listing guidelines of the NYSE or other known exchanges, although they are mandated to file financial statements with known regulators, such as the SEC. Penny shares are inexpensive, thus attractive to shareholders who lack the funds to buy comparatively expensive blue-chip stocks from large firms.

Penny stocks boast immense profit potential. Because these stocks trade cheap, even a slight jump in price turns to be profitable. Look out, however, because frequently shareholders may have trouble getting a decent amount of details about penny stocks. These kinds of shares tend to be latest in news, with almost no track record for investors research.

In addition, penny stocks show lack of market activity, with poor liquidity, making them difficult to sell. Poor liquidity results in penny stocks to be open to price influence.

A shady trader can simply buy large sums of shares, temporarily leading up the price, crafting artificial demand.

Disclaimer: Nothing mentioned in this publication is planned to constitute legal, securities, tax, or investment advice, nor a viewpoint regarding the relevance of any investment, nor any type of solicitation. The general information mentioned in this article should not be acted upon without getting specific tax, legal and investment advice from a certified professional.

More important recent U.S. Stem Cell, Inc. (OTCMKTS:USRM) news were published by: which released: “US Stem Cell, Inc.’s MARVEL Phase II/III Trial Receives Reactivation Status …” on April 10, 2017, also published article titled: “General American Capital Partners Invests up to $5 Million in US Stem Cell, Inc.”, published: “US Stem Cell, Inc. and Advanced Stem Cell Rx Develop Strategic Alliance” on March 30, 2017. More interesting news about U.S. Stem Cell, Inc. (OTCMKTS:USRM) was released by: and their article: “US Stem Cell Responds to FDA’s Regenerative Medicine Guidelines” with publication date: November 21, 2017.

U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. The company has market cap of $14.33 million. The Company’s lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patientÂ’s heart with autologous muscle cells or cells from a patientÂ’s body for improving cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, lower limb ischemia, and rheumatoid arthritis. It currently has negative earnings. The companyÂ’s product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.